Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jinf.2024.106165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study.
Lancet Reg Health Am
December 2024
Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
Background: The Canadian National Vaccine Safety Network conducted active safety surveillance for COVID-19 vaccines. This study aimed to characterize the short-to-medium term safety of mRNA COVID-19 vaccines across the pediatric age spectrum.
Methods: In this cohort study, vaccinated and unvaccinated children and adolescents aged 6 months to 19 years from eight Canadian provinces and territories were invited to participate.
Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
Front Immunol
November 2024
Center for Clinical and Nutritional Chemistry, School of Chemistry, University of the Punjab, Lahore, Pakistan.
Article Synopsis
- The study investigates the effects of heterologous (different) and homologous (same) COVID-19 vaccine booster doses in healthy adults in Pakistan, focusing on immune responses nine months post-vaccination.
- A total of 173 participants aged 18-25 received either Sinopharm BBIBP-CorV or Pfizer-BioNTech vaccines, with antibody levels measured to compare immune responses.
- Results show that the Pfizer group had significantly higher IgG antibody levels compared to the Sinopharm group, suggesting that a third Pfizer dose after two Sinopharm doses enhances overall immune response, with no significant differences between genders.
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
Vaccine
December 2024
School of Health Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia; Malaysia Genome and Vaccine Institute, National Institutes of Biotechnology Malaysia, Jalan Bangi, 43000 Kajang, Selangor, Malaysia. Electronic address:
This prospective cohort study examines the long-term humoral immune responses post-COVID-19 vaccination in 146 individuals who received either a homologous three-dose BNT162b2 vaccine regimen (PPP) or two primary doses of CoronaVac followed by BNT162b2 booster (SSP) in Malaysia. The study focuses on serum anti-S1-RBD-IgG, -IgA, and -IgM, using the ELISA method. The results show that BNT162b2 outperformed CoronaVac in the two dose primary vaccination series.
View Article and Find Full Text PDFRisk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
Vaccine
December 2024
Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia. Electronic address:
Objective: To assess the potential risk of major adverse cerebro-cardiovascular events (MACCE) associated with COVID-19 vaccination and SARS-CoV-2 infection.
Methods: This self-controlled case series study used nationwide health database from Malaysia. The study included individuals aged ≥18 years who were hospitalised between 24 February 2021 and 30 June 2022.
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
iScience
September 2024
Unidad de Inmunopatología del SIDA, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Majadahonda, 28222 Madrid, Spain.
CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!